Ionis Pharmaceuticals / Ultragenyx Pharmaceutical: Spotlight on Angelman Syndrome: important catalysts coming up

Research evidence excerpt

Ionis Pharmaceuticals / Ultragenyx Pharmaceutical: Spotlight on Angelman Syndrome: important catalysts coming up

Barclays | Ionis Pharmaceuticals / Ultragenyx Pharmaceutical

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is

directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of

"investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high

net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c)

other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity

to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this

communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the

Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area (“EEA”): This material is being distributed to any “Authorised User” located in a Restricted EEA Country by Barclays Bank

Ireland PLC. The Restricted EEA Countries are Austria, Bulgaria, Estonia, Finland, Hungary, Iceland, Liechtenstein, Lithuania, Luxembourg, Malta,

Portugal, Romania, Slovakia and Slovenia. For any other “Authorised User” located in a country of the European Economic Area, this material is being

distributed by Barclays Bank PLC.